EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of resistance to antibody-drug conjugates in bladder cancer

Kai Liu, Feixiang Xu, Chenyang Wu, Miao Wang

Frontiers in Pharmacology · 17.08.2026 · 17

DOI: 10.3389/fphar.2026.1882868 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.08.2026. Verfasst von Kai Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) have made important advances in the treatment of bladder cancer (BC) in recent years and have demonstrated significant clinical benefit in locally advanced or metastatic urothelial carcinoma (UC). However, the emergence of resistance remains a key factor limiting the durability of their therapeutic efficacy. Current evidence indicates that resistance to ADCs in BC is a complex process driven by multiple tumor-intrinsic and tumor-extrinsic factors. This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers. A deeper understanding of BC-specific mechanisms of ADC resistance will help promote the development of more precise and individualized ADC-based treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

antibody-drug conjugatesbladder cancercombination therapydrug resistanceresistance mechanisms

Autor:innen und Institutionen

  • Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Zitieren

APA

Liu, K., Xu, F., Wu, C., & Wang, M. (2026). Mechanisms of resistance to antibody-drug conjugates in bladder cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1882868

Vancouver

Liu K, Xu F, Wu C, Wang M. Mechanisms of resistance to antibody-drug conjugates in bladder cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1882868

BibTeX
@article{Liu2026,
  author = {Liu, Kai and Xu, Feixiang and Wu, Chenyang and Wang, Miao},
  title = {Mechanisms of resistance to antibody-drug conjugates in bladder cancer},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1882868}
}
Kostenlos starten →